Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is what we know we have:
1) Producing ITV-1 for Africa and clinical trials
2) Producing IPF Immune for distribution in the US
3) There are trials going on at University of Strasbourg. Animal trials on France that are due soon.
4) New distributorship in South America with RobustoMed
5) Filed a minimum of 18 new patents since Nov 2020
6) Developed AI
7) White paper with Intel
8) Press Release with Samsung
9) Sold distributorship - will get 1/2 ownership of Pharma plant in Bulgaria when permit is issued.
10) Started clinical trials in EMA
Did you all see the Samsung press release?
Companies like that do not make up stuff. ENZC/Samsung relationship is real.
https://markets.businessinsider.com/news/stocks/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2-monoclonal-antibody-therapies-1030850027
Here we go again
Read the supplemental info provided by the company that gives a detailed analysis . The float increased in 2019 and 2020. All the increase in float traded many times over since 9/30/2020.
Looking at Yahoo historical trading data, there have been about 7.6 BILLION shares traded since the end of 2020 (that is adding up the daily volume of shares traded). Any shares that settled long ago have clearly been sold and resold many times - they have been fully absorbed LOOOOOOOONG AGO. Certainly mostly prior to the stock price run up - from $0.0001 to $0.077 or so today.
“Float” has turned over many times - all the shares are in public hands.
Simple math shows that it’s impossible for their trading to be anything remotely like a pump and dump.
Lots of discussions about new shares. Here is some technical analysis of a particular set of transactions regarding Livingston.
Let’s look at the ENZC trading volume back in March of 2020:
https://finance.yahoo.com/quote/ENZC/history?period1=1582934400&period2=1584921600&interval=1d&filter=history&frequency=1d&includeAdjustedClose=true
Daily volume is shown in black. Certain dates, shown in blue, have virtually zero volume - Look at the two dates, one with zero (!) volume and the other with 300 shares at $0.0002 - a 6 cent trade - lololol.
THEN on March 12, 2020, Livingston is issued 114 million shares. The day earlier, March 11, 2020, the volume shoots up from virtually nothing to 155 million shares @ $0.0002 - $31,000 total, shown in red.
It's painfully clear that all the issuance of 114 million shares of stock to Livingston on March 12 was known and sold the previous day (March 11) for about $31,000. It is obvious that on this particular transaction, the shares issued were sold into the market, and remain in the public float to this day.
This pattern exists at every issuance of 3(a)10 shares to Livingston.
All upside in the shares was clearly realized by those retail investors who purchased the Livingston shares and sold later during one of the multiple turns of the float.
https://investorshub.advfn.com/uimage/uploads/2022/3/18/TPQGGVAUVTAMWVKZXBY.png
Let's clarify the rules (SEC 144) for issuing shares:
If shares are issued to insiders, by SEC 144 rules, the following has to happen:
- The transaction has to be disclosed in the proper filings.
- There is a waiting period of 2 years before the shares can trade freely (ie. enter the float).
If shares are issued, that is “dilution”, if shares trade freely, that is “float.”
In the case of ENZC, there have been no new original shares issued since Oct 2020. Therefore, no dilution. (Unless one thinks that ENZC has illegally done so without disclosing to FINRA/SEC).
And, the shares that have matured into the float (that were issued over 2 years ago) have done so in a normal and natural way.
But since ENZC operates within the rules, we can all be assured that dilution is not happening.
***If anyone knows of share scams or illegal activity on any stock, please report to FINRA/SEC. ***
Bringing drugs to market is complicated. Many factors involved. Different companies are subject to different restrictions, some of which we know and some we don’t. Every company has things that they are good at and things that they outsource. In fact, most companies (drug and non-drug) outsource an enormous amount of work. The largest companies and governments recognize that specific expertise is extraordinarily difficult to keep in house. That is normal in the current complex world-wide economy.
The fact ENZC is still being supported while the products are in development means: the people that matter believe in the statements made.
Looks to me like CC is referring to the AI doing something unique. Looks cool to me.
End of day art class coming….beware.
How about some love in my direction?
Looked into enough to do a press release....
You think large companies like Samsung just partner with anyone?
Again with the Weird Definitions....
"Outstanding shares" does not equal "float"
Unrestricted shares are normal and natural and have been disclosed for a long time.
Smart investors should consult the OTC filings.
And the PR's of the company
And 3rd party validation.
Instead of looking at weird, made up scenarios, sheesh.
ENZC has 4 executive Officers. None have an accounting degree, but an assortment of other degrees from prestigious schools and institutions.
This is a drug development company and sales aren't the main factor.
Frankly, smart investors should be considering evidence of product development and testing.
There is no hidden information - it's all on the OTC filings.
Notice how some ignore 3rd party validation.
ENZC does not make those statements, Samsung does.
It's sad to look at the baseless speculation
Did you all see the Samsung press release?
https://markets.businessinsider.com/news/stocks/enzolytics-inc-and-samsung-biologics-announce-development-and-manufacturing-agreement-for-anti-hiv-and-anti-sars-cov-2-monoclonal-antibody-therapies-1030850027
With all the company has going on I am surprised that they have time to file an extension and get filed within the extended date like they have.
Facts are for investors
This is what we know we have:
1) Producing ITV-1 for Africa and clinical trials
2) Producing IPF Immune for distribution in the US
3) There are trials going on at University of Strasbourg. Animal trials on France that are due soon.
4) New distributorship in South America with RobustoMed
5) Filed a minimum of 18 new patents since Nov 2020
6) Developed AI
7) White paper with Intel
8) Press Release with Samsung
9) Sold distributorship - will get 1/2 ownership of Pharma plant in Bulgaria when permit is issued.
10) Started clinical trials in EMA
Red Herring.
Why would an issue from non-ENZC company be an issue for ENZC? And that issue is 8 years ago?
IIRC, the issue back in 2014 was a 10-day suspension of IMMB. Nothing came of the suspension, and then trading was allowed to resume. Clearly, if there was something there, the authorities would have done something, but no further action was taken.
All this was a previous company, long ago and prior to the merger that created Enzolytics.
Average 30 day volume has dropped from 16 m/day in Feb to about 6 m/day now.
Looks to me like more like accumulation by real investors, rather than a selling scam. No longs are selling so price floats some.
Let's look at Restricted Shares vs. Unrestricted Shares:
Maturing stocks are a normal and natural process.
There are about 2.2 billion Unrestricted Shares, with Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now.
The only shares still restricted that arent accounted for are shares held by officers, shares tied up in litigation.
70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.
DEBUNKED!!! Livingston Shares and ENZC
Here is a repost of an analysis I did last week:
Some technical analysis of a particular set of transactions regarding Livingston.
Let’s look at the ENZC trading volume back in March of 2020:
https://finance.yahoo.com/quote/ENZC/history?period1=1582934400&period2=1584921600&interval=1d&filter=history&frequency=1d&includeAdjustedClose=true
Daily volume is shown in black. Certain dates, shown in blue, have virtually zero volume - Look at the two dates, one with zero (!) volume and the other with 300 shares at $0.0002 - a 6 cent trade - lololol.
THEN on March 12, 2020, Livingston is issued 114 million shares. The day earlier, March 11, 2020, the volume shoots up from virtually nothing to 155 million shares @ $0.0002 - $31,000 total, shown in red.
It's painfully clear that all the issuance of 114 million shares of stock to Livingston on March 12 was known and sold the previous day (March 11) for about $31,000. It is obvious that on this particular transaction, the shares issued were sold into the market, and remain in the public float to this day.
This pattern exists at every issuance of 3(a)10 shares to Livingston.
All upside in the shares was clearly realized by those retail investors who purchased the Livingston shares and sold later during one of the multiple turns of the float.
https://investorshub.advfn.com/uimage/uploads/2022/3/18/TPQGGVAUVTAMWVKZXBY.png
The shares falsely referred to as currently “diluting” were issued in 2019/2020 - as shown in the supplemental info. There was no dilution in 2020/2021 because of the disclosures that show increase in Outstanding Shares.
All the impact from any additional shares issued in 2019 and 2020 was realized at that time. That’s when the Livingston shares were clearly sold in the market, and they have clearly turned numerous times. The Livingston shares transferred at prices below $0.0145 and are in the public hands.
(And by the way, the price is up substantially AFTER those shares were clearly sold became unrestricted - up to $0.08.)
Livingston had a zero position in Enzc shares at 11-01-2020. Trace the conversions and the increase in trades on the historical data on trades.
The increase in float was normal and natural and followed SEC 114 guileless - from individuals that invested prior to 10/15/2020 and elected to remove the restrictions.
Correction: 800 TIMES or 80,000% return.
I struggle with math, too, sometimes. ;)
Perfectly normal (and exciting) drug development company.
Price is up 800 times from Summer of 2020.
Where is the problem? if it's an issue, report it to FINRA/SEC. But those who trash will not do that, because it's easy to make statements with no evidence.
Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now.
70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.
Isn't this standard "safe harbor" language?
I believe so.
Today's press release is heartening
Shows solid progress in the US.
Combine this with the previous news:
- There are 2 hospitals in the heart of the HIV epidemic who want to move forward.
- They are looking to treat up to 30,000 patients!
- IPF Immune has been announced to hit the market.
I was imprecise.
FDA Approval for a drug is a long, drawn out affair. The press release says the following:
"The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083"
The registration and assignment of a number for a supplement is still a pretty big deal. They do not give out those numbers lightly and it's quite rare for such evidence.
The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083
Sounds pretty good to me.
FDA approved - under NDI reg. no. 1083.
Note the number "1083". The FDA doesn't give a number unless approved. And, they don't give out very many....
IPF Immune is an FDA approved immune booster...
Not too many immune boosters are FDA approved.
Unrestricted shares maturing is not dumping (sigh) - it's normal and natural aging.
Regardless, as I mentioned earlier, there are only about 3% of restricted shares that are truly eligible to become unrestricted. That's hardly a significant problem.
The PR specifically said that ENZC
Is going to present in front of buyers next week. Pretty clear.
The PR is pretty clear to me.
They are debuting IPF Immune next week and it will be available "soon to American consumers"
No one can “dump into the float”. Maturing stocks are a normal and natural process.
Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now.
70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.
Price is actually is up 800 times from summer of 2020.
ENZC rarely puts out press releases, and they tend to be technical/scientific PR’s. Very thorough, not exactly fluff.
IPF Immune is announced to be an immune booster, not a food supplement. The underlying formula is similar to ITV-1, which has been referred to as a cure by Samsung.
This morning’s press release states the ENZC position on IPF Immune: ”Enzolytics' immune modulator supports immune function by positively supporting the immune system," said Harry Zhabilov, CSO of Enzolytics, Inc. "We have devoted years to developing an immune modulator that fortifies your natural defenses.”
"When you take Enzolytics IPF Immune™, it strengthens the body's response against viruses or other pathogens," Mr. Zhabilov added. "Enzolytics IPF Immune™ mitigates the damage that the viruses can do."
Refer to comments above.
Those supposed “red flags” have all been debunked. If they were really red flags, something would have happened by now.
Joseph, the inventor of Clone-3, is one of the most valuable assets that ENZC has. All issues have been long resolved.
There is a difference between lying and inexperience/naïveté. Apparently, this is the first public entity in which these individuals have held positions. On-the-job training.
Facts are for investors.
Welcome to the cutting edge of drug development.
Dyno is correct.
Any corporate info prior to the merger is useless. The merger changed the corporate and financial structure to a degree that it's not plausible to compare.
The merger was, however, great for those shareholders; as shown by the stock price increase from $0.0001 to $0.08, an 800 times improvement. While this price has skyrocketed, there have been no shares issued from convertible debt, or shares issued for services since Dec. 2020, zero dilution.
Regarding revenue: a drug development company frequently has zero revenue for awhile. THEN, things happen.
Look to evidence of positive things for ENZC to see if potential is there. For example:
IPF Immune being announced in the US and other countries
New distributorships
ITV-1 promising movement in Africa
Intel and Samsung seem to know what's happening.
Smart observers can see good things happening.
This is an easy one:
1) No new shares issued since Oct 2020
2) No restrictions removed from the shares issued to officers for the transaction
3) Those officer shares were allocated not from ENZC, but unselfishly by Harry Zhabilov directly - unlocks value to all shareholders
Just for the record - a pump and dump https://en.wikipedia.org/wiki/Pump_and_dump
is securities fraud. If anyone sees that, they need to report to FINRA/SEC right now!
(But, that's not happening. Proof: Zero documentation from FINRA/SEC - such documentation would be present if securities fraud existed.)
The FINRA/SEC monitors for these allegations aggressively and would document. They do NOT respond to unfounded allegations.
And the stock price is up 800 times from summer of 2020.
It's lazy to look at any stock's high price and say that it's current price relative to it's high is proof that it's failing. By that measure, 99.9999% of companies are failing.
How would anyone know what he knows...
without a crystal ball and some tarot cards?
If there is some violation, it should be reported to the authorities. Based on what is being posted here, there would be a string of reporting to FINRA/SEC, etc.
But, strangely, there is nothing published from those organizations against ENZC who have institutional oversight and the integrity to be able to sort through wild, baseless accusations.
An Investor Relations company is SUPPOSED
to promote the company. THAT'S THE WHOLE POINT.
Drug development companies develop drugs...then sell them.
This is EXACTLY the path that ENZC is on. 17 antibodies patented, all in the last year and a half.
Plus the progress on ITV-1 after the failure with the first Bulgarian partner (Savov).
Also, Clone 3 foundation treatments from before the Bioclonetics transaction.
A pretty good set of facts.